Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB11 vs Lucentis in Neovascular AMD
NCT03150589Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of SB-11 in neovascular age-related macular degeneration (NVAMD), sponsored by Samsung Bioepis. Started Mar 2018; status: completed.
02
Drugs
SB-11
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03150589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150589.